News
Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...
Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...
Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.
Merck, Black Hills, and Virtus Investment Partners are good choices for investors seeking reliable passive income. Their ...
Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...
With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...
Merck said it still expects 2025 total sales ... We sell different types of products and services to both investment professionals and individual investors. These products and services are ...
Merck & Co., Inc. operates as a healthcare company ... Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback